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Guillain-Barre syndrome (GBS) is an immune-mediated polyneuropathy
that occurs mostly after prior infection. The diagnosis of this syndrome is
dependent heavily on the history and examination, although cerebrospinal
fluid analysis and electrodiagnostic testing usually confirm the diagnosis.
This is a retrospective study which was performed to investigate the atypical
features of GBS.
Materials & Methods
Thirty three patients (21/63.6% males and 12/36.4% females) with GBS were
retrospectively studied and prospectively evaluated at the Child Neurology
institute of Mofid Children Hospital of Shahid Beheshti University of
Medical Sciences between May 2011 and September 2012.
Results
The mean age was 5.4 years (range, 1.5-10.5).Twenty one patients (87.9%)
had previous history of infections. Eight patients (24.2%) admitted with
atypical symptoms like upper limb weakness (3%), ptosis (3%), neck
stiffness (3%), inability to stand (proximal weakness) (9.1%), headache
(3%) and dysphagia (3%).According to disease process, weakness was
ascending in 26 (78.8%), descending in 5 (15.2%) and static in 2 (6.1%)
patients. Cranial nerve involvement was found in 8(24.3%) children, most
commonly as facial palsy in 3 (9.1%).
Conclusion In this study, 24.3% of our patients presented with atypical
symptoms of GBS as upper limb weakness, ptosis, neck stiffness, inability
to stand (proximal weakness), headache and dysphagia.
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Introduction
An acute inflammatory demyelinating polyneuropathy (AIDP) which has
autoimmune basis affecting the peripheral nervous system is called Guillain –Barré
syndrome (GBS). Nowadays Guillain–Barré syndrome is the most common cause
of acute neuromuscular paralysis in the world. A French physician first described a
variant of this syndrome in 1859, so it is sometimes called Landry’s paralysis. After
the French physicians, this syndrome was detailed by Guillain, Barré and Strohl,
in 1916. The disease has become well-known internationally under the name of
Guillain Barré Syndrome (1,2).
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The highest incidence of GBS is in two ends of the
human life in early and late adulthood. The disease
affects young adults greater than the elderly with a
slightly higher male preponderance with a ratio of
1.25-1.5:1 (3). In Iran, the incidence of GBS has been
reported between 1.5 and 3.4/100,000 versus 0.4 and
0.6/100,000 in western countries (4,5).
The disease is assumed to be autoimmune and operated
by a preceding infection, most of the time respiratory
or gastrointestinal infections. Generally infections by
microorganisms such as Campylobacter jejuni, CMV,
Mycoplasma pneumonia, or influenza virus exist
several weeks prior to approximately two thirds of GBS
cases (6).
Epitopes on the surface of peripheral nerves
(gangliosides, glycolipids) resemble some infectious
agents’ surface epitopes so the immune system attacks
peripheral nerves erroneously (6). GBS usually begins
abruptly with distal, relatively symmetrical onset
of paresthesias. Progressive limb weakness starts
simultaneously or immediately after the sensory
discomfort. Affected patients are able to remember the
apparent onset of the disease symptoms. With a rapid
progression, fifty percent of patients overtake clinical
nadir by 2 weeks and more than 90% by 4 weeks (7).
Miller Fisher syndrome, acute inflammatory
demyelinating polyradiculoneuropathy (AIDP), acute
motor axonal neuropathy (AMAN) and acute motor and
sensory axonal neuropathy (AMSAN) are considered as
four principal subtypes of this syndrome. Oculomotor
dysfunction, ataxia and areflexia are triad symptoms
of the Miller Fisher syndrome (8). Symptoms such
as: progression of motor deficit, relative sensory
symptoms or signs likes: elevated levels of protein in
the cerebrospinal fluid and electrodiagnostic features
such as nerve conduction slowing are criteria for
GBS diagnosis (9). Temporal dispersion, significantly
slow conduction velocities and prolonged distal and F-
wave latencies are demyelinating findings of
electrodiagnostic testing (EDX) of GBS.
Electrodiagnostic testing results such as conduction
block, temporal dispersion and nonuniform slowing
of conduction velocities are useful in the diagnosis of
the disease because they are specifications of immune-
mediated demyelination (10).
Patients with the confirmed diagnosis of GBS will
be treated with plasmapheresis or intravenous
immunoglobulin (IVIG). Some patients should be
under respiratory support when needed. Ventilator
support is the requirement of approximately twenty
five percent of GBS cases, particularly patients with
more rapid motor weakness progression. The efficacy
of plasmapheresis and IVIg in the treatment of GBS
has been equal. Intravenous immunoglobulin (IVIG)
is the treatment of choice of these patients because it
is easier to use. Current recommendations corroborate
the opinion that the steroid regimen has no more
advantage when added to therapy, although this issue
is controversial. Longitudinal gradual improvement
will be the consequence of treatment in most patients
in weeks to months. Affected patients with more
aggressive onset tend to have more poorly recovery. Ten
to twenty percent of these cases are complicated with a
disabling motor deficit overall (11-13).
In this study, we evaluated patients with GBS series
between 2011-2012, with the purpose of defining its
atypical epidemiological, clinical, laboratorial findings
and follow-up profile.
Materials & Methods
This series of patients with Guillain-Barré syndrome
were retrospectively studied and prospectively
evaluated at the Child Neurology Institute of Mofid
Children Hospital of Shahid Beheshti University of
Medical Sciences between May 2011 and September
2012. The Child Neurology Institute of Mofid
Children Hospital is a third level pediatric hospital
that receives patients from throughout the country.
The patients fulfilled the clinical criteria for Guillain-
Barré syndrome (14). Based on the patient’s history,
physical examination and paraclinic findings, the
typical ascending form of Guillain-Barré syndrome was
characterized by progressive, symmetric, ascending
flaccid paresis with areflexia. The atypical presentation
group of Guillain-Barré syndrome was characterized
by localized or regional involvement of the motor
and sensory axons of the peripheral nerves and the
autonomic nervous system (15,16). Acute inflammatory
demyelinating polyradiculoneuropathy (demyelination
and axonal forms), acute motor-sensory axonal
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neuropathy and acute motor axonal neuropathy classified
as the typical ascending GBS. Atypical presentation
included prominent cranial nerve involvement, Miller
Fisher syndrome, Bickerstaff brainstem encephalitis,
pharyngo-cervical-brachial and polyneuritis cranialis
and others, which included acute pandysautonomia and
acute sensory neuropathy (17,18).
All patients were reviewed clinically by a child
neurologist. The electrophysiology was performed
at the neurophysiology section of Mofid hospital.
Data was prospectively collected from all GBS cases
and subsequently, cases were analyzed separately.
The diagnosis was based on clinical features, lumbar
puncture and electrophysiological findings as laid down
in the well-established criteria. Onset of weakness,
duration of weakness, associated or preceding events
and progression of the disease were recorded. A detailed
neurological examination was recorded in all patients.
The nerve conduction velocity (NCV) studies were
done within 24 hours of hospitalization. At least one
motor and one sensory nerve were tested in upper and
lower limbs. F-wave latencies were recorded if there
was only mild slowing of nerve conduction velocity.
Electromyography (EMG) was not performed in any
patient. All confirmed GBS cases were followed up for
3 months after onset.
Results
During a period of 16 months, 33 children including
21 (63.6%) males and 12 (36.4%) females with the
confirmed diagnosis of GBS were enrolled in this study.
The mean age was 5.4 years (range, 1.5-10.5 years).
Twenty one patients (87.9%) had a previous history of
infection. The most
common preceding events of the GBS occurred in
winter and were respiratory infections (14 cases,
42.4%), followed by gastrointestinal infections (11
cases, 33.3%), dental infection (two cases, 6.1%),
chicken pox (one case, 3%) and heart surgery (one case,
3%). In four other patients (12.1%) no triggering factor
was found. The interval between these events and the
onset of disabilities ranged from 3 to 15 days (mean,
9.5 days).
The most common presenting symptoms were lameness
that was seen in 10 (30.3%), gait imbalance in six
(18.2%), lower limb weakness in five (15.2%), steppage
gait in two (6.1%) and myalgia in two (6.1%) of the cases.
Eight patients (24.2 %) were admitted with atypical
symptoms like upper limb weakness (3%), ptosis
(3%), neck stiffness (3%), inability to stand (proximal
weakness) (9.1%), headache (3%) and dysphagia (3%).
Lower limb deep tendon reflexes (DTR) were reduced
or could not be detected in 27 (81.8%) where upper
limb deep tendon reflexes (DTR) were reduced or
could not be detected in 11 (33.3%) cases. According
to the disease process, weakness was ascending in 26
(78.8%), descending in five (15.2%) and static in two
(6.1%) patients. Cranial nerve involvement was found
in eight (24.3%) children, most commonly as facial
palsy in three (9.1%), followed by bulbar weakness (gag
reflex abnormalities) in two (6.1%), abducence palsy in
two (6.1%) and trigeminal palsy (ophthalmoplegia) in
one (3%) patient. Five patients (15.2%) had sphincter
dysfunction of which all were urinary incontinency. Nine
patients (27.3%) complained of muscle pain and other
sensory symptoms. A lumbar puncture was performed
in all cases within two weeks of the onset of the illness.
The CSF protein concentration was raised (>45 mg/dl)
in 23 (69.6%) patients and the mean concentration was
59.8 mg/dl (range, 15-153 mg/dl). CSF pleocytosis was
not found.
Nerve conduction velocity findings were as acute
demyeliniting in 21 (63.6%), axonal in six (18.2 %) and
absent F wave in six (18.2%) patients. Based on clinical
and electrophysiological investigations, 29 (87.8%) of
the cases were classified as AIDP, two (6.1%) of the
cases were classified as CIDP and two (6.1%) as Miller
Fisher syndrome (MFS). In three patients that were
diagnosed as acute GBS, the cauda equine displayed
hyperintense thickening in spinal MRI. Nine (27.2%)
patients were admitted in PICU and ventilation support
was needed for four (12.2%) of them.
Twenty six patients received IVIG and four of them
received intravenous methylprednisolone too. Four
of the patients were treated with plasmapheresis after
IVIG - corticosteroid failure and three cases were cured
without any medication. The length of hospital stay
ranged from 5 to 36 days (mean 7.5 days).
After treatment, 19 patients (57.6%) developed
significant improvement of functional disability one
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month later, five of them (15.1%) ameliorated after 3
months and nine (27.3%) patients have not reached
complete recovery till now. Among untreated children,
two have waddling gait, five have inability to stand, one
has steppage gait and two have limb lameness.
Discussion
We have reported eight children who include 24.3%
of the total patients who have presented with atypical
symptoms of GBS as upper limb weakness (3%), ptosis
(3%), neck stiffness (3%), inability to stand (proximal
weakness) (9.1%), headache (3%) and dysphagia (3%).
Jin Park et al. reported an 11-year-old girl with an atypical
GBS presentation of generalized weakness, internal
ophthalmoplegia (visual dimness, anisocoric pupils) and
postural dizziness; The current study is consistent with
the symptoms of a 10-year-old girl who was admitted
with ptosis and weakness in our study (19).
A 1.5-year-old boy was referred to our hospital with neck
stiffness and myalgia. Central nervous system infections
were ruled out by CSF analysis and electrophysiologic
investigation found acute demyelinating neuropathy
as GBS. This is similar to the report of atypical GBS
by Etem Pişkin et al. who diagnosed  a 3-year-old
girl who suffered from prominent neck stiffness and
positive Kernig’s and Brudzinski’s signs. Muscle
weakness increased significantly on the second day of
hospitalization and the patient lost her ability to walk by
the third day (20).
In our series of 33 children with the diagnosis of GBS,
87.8% had clinical and electrophysiological findings
suggesting AIDP; 6.1% of the cases were classified as
CIDP and 6.1% as Miller Fisher syndrome which is
concordant with previous studies.
In North America and Europe, Miller-Fisher syndrome
has been found to account for approximately 5% of the
GBS cases (8).
The male to female ratio was 1.75:1, while previous
reports presented a ratio of 1.25-1.5:1 (21). Most authors
described a discrete prevalence of GBS in males. On the
other hand, van der Linden et al. reported no significant
discrepancy between the two genders regarding the
incidence of GBS (22).
Twenty one patients (87.9%) had previous history of
infections with a mean interval between these events
and disability onset of 9.5 days. Two most common
preceding events of the GBS were respiratory (42.4%)
and gastrointestinal infections (33.3%). Generally,
more than two-thirds of GBS cases have a past medical
history  of  acute  illness,  most  commonly  infection
of  the  respiratory  tract  or  gastrointestinal  system
which have been eliminated since the neuropathic
symptoms initiated. In several large studies, the time
duration between the precedent infection and the
symptoms of GBS differs from 1 to 3 weeks which is
sometimes longer. In many large studies, the average
of 11 days has been reported. Precedent respiratory
and gastrointestinal infectious symptoms encompassed
17% to 38% of the patients with GBS in a study
conducted by Winer et al. (23).
This study showed that the highest proportion of the
syndrome was observed in the winter; however. the
syndrome assumed to be sporadic with no significant
disparity between seasons or months. This finding
is in agreement with a study performed by Barzegar
et al. which showed a relationship between the high
frequency of upper respiratory tract infections within the
cold season and the high incidence of GBS syndrome
in winter (24). A study from China demonstrated that
campylobacter jejuni infections in summer might create
epidemics of this syndrome. The seasonal incidence of
40% has been reported for GBS in cold seasons with
the maximum peak in February in a study carried out in
Saudi Arabia (24,25).
The weakness was ascending in 78.8% of the patients;
however, in 15.2% the initial symptoms involved
the upper limbs. The involvement of cranial nerves
occurred in 24.3% of the patients, VII nerve being the
most attacked, usually unilateral; which was different to
that found in the literature (26).
The pattern of cranial nerve involvement in a study
conducted by van der Linden et al. on the clinical and
epidemiological aspects of Guillain-Barré syndrome
in children was bilateral facial nerve paralysis in
55.7% (22).
The mean recovery period in children reported in the
literature was about 50 days, which is rather a short
time. Total time for recovery of GBS is shorter in
younger patients compared with adults. Nine patients
(27.3%) persisted with sequels after a period of 16
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months follow-up, which is in agreement with that
found in the literature (27,28). However, the sequel
rate reported here is higher than some studies, because
Mofid hospital is a third level pediatric hospital that
receives patients from throughout the country including
those without complete recovery.
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